Bio-Rad Laboratories anti-biotherapeutic and anti-MMAE antibodies

Wednesday, 10 July, 2024 | Supplied by: Bio-Rad Laboratories Pty Ltd


Bio-Rad Laboratories has launched four anti-idiotypic antibodies to the drugs atezolizumab (Lemtrada), avelumab (Bavencio), obinutuzumab (Gazyvaro) and ocrelizumab (Ocrevus), extending its range of anti-biotherapeutic antibodies. It has also introduced its anti-monomethyl auristatin E (MMAE) biotherapeutic antibody range for bioanalysis.

The company’s range of ready-made anti-biotherapeutic antibodies enables the development of robust bioanalytical assays against marketed biologic drugs. The anti-idiotypic antibodies are suitable for pharmacokinetic (PK) and antidrug-antibody assays for atezolizumab, avelumab, obinutuzumab and ocrelizumab, enabling therapeutic drug monitoring for innovator and biosimilar products.

The anti-MMAE antibody range supports bioanalysis of antibody-drug conjugates (ADCs) carrying MMAE as payload. MMAE is a potent antimitotic agent that inhibits cell division. Due to its toxicity, MMAE is not used as a drug itself, but instead forms the payload component of ADCs. The anti-MMAE biotherapeutic antibodies enable the development of sensitive assays for both ADCs incorporating the toxin and the toxin itself.

Online: www.bio-rad.com
Phone: 02 9914 2800
Related Products

Amsbio BioPORTER Protein Delivery Reagent

The BioPORTER Protein Delivery Reagent from Amsbio is a specialised, lipid-based reagent designed...

Amsbio StemFit Basic04CT stem cell medium

StemFit Basic04CT from Amsbio is an animal-origin-free, defined, ready-to-use medium designed to...

Takara Bio Europe Cellartis MSC EV Wonder GMP-grade medium

Takara Bio Europe has introduced a Good Manufacturing Practice (GMP)-grade version of Cellartis...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd